Clinical Trials Logo

Filter by:
NCT ID: NCT02242942 Active, not recruiting - Clinical trials for Lymphocytic Leukemia, Chronic

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Start date: December 31, 2014
Phase: Phase 3
Study type: Interventional

This open-label, multicenter, randomized Phase III study is designed to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax versus obinutuzumab + chlorambucil in participants with chronic lymphocytic leukemia (CLL) and coexisting medical conditions. The time on study treatment was approximately one year and the follow-up period will be up to 9 years.

NCT ID: NCT02236806 Active, not recruiting - Breast Cancer Clinical Trials

Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab

SAFE
Start date: July 2015
Phase: Phase 3
Study type: Interventional

The aim of the study is to analyze the protective impact on the cardiac damage of beta blockers and ACE inhibitors for breast cancer patients treated with anthracyclines-based chemotherapy with or without trastuzumab.

NCT ID: NCT02232386 Active, not recruiting - Adult Patients Clinical Trials

Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia

LLC1114
Start date: March 2, 2015
Phase: Phase 2
Study type: Interventional

The present study aims at evaluating whether treatment with two different drugs, Ibrutinib and Rituximab is both efficient and safe for newly diagnosed patients with chronic lymphocytic leukemia.

NCT ID: NCT02231749 Active, not recruiting - Clinical trials for Metastatic Renal Cell Carcinoma

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Start date: October 16, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.

NCT ID: NCT02226679 Active, not recruiting - Heart Failure Clinical Trials

An Open Label Rollover Trial for Patients Randomized to the Control Group of Study LSH-10-001

Start date: January 2014
Phase: N/A
Study type: Interventional

The objective of this extension study is to evaluate the safety and potential beneficial effects of the Algisyl-LVRâ„¢ device in patients with established heart failure secondary to a dilated cardiomyopathy. The results of this study will provide confirmatory evidence of the long-term safety and effectiveness of the Algisyl-LVR in patients with established heart failure.

NCT ID: NCT02223208 Active, not recruiting - Clinical trials for Peripheral T-cell Lymphomas (PTCL)

Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas

FIL_PTCL13
Start date: September 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter study that includes two phases: 1. A phase I study to define the maximum tolerated dose (MTD) of Romidepsin in addition to CHOEP-21 and to test the safety and feasibility of CHOEP-21 in combination with dose escalation of Romidepsin (8, 10, 12, 14 mg). The dose level defined as MTD of Romidepsin will be used for the subsequent phase II study. 2. A phase II study to evaluate the efficacy (response rate, progression free survival and overall survival) and safety of Ro-CHOEP-21 incorporated into a treatment strategy including SCT.

NCT ID: NCT02215980 Active, not recruiting - Multiple Myeloma Clinical Trials

STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS

Start date: July 2014
Phase: Phase 3
Study type: Interventional

This protocol is a phase III multicenter, randomized, controlled study designed to assess the safety and the efficacy of standard schedule versus a new algoritm of dose reductions in elderly and unfit newly diagnosed Multiple Myeloma (MM) patients receiving lenalidomide plus steroids.

NCT ID: NCT02213926 Active, not recruiting - Clinical trials for Mantle Cell Lymphoma (MCL)

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Start date: March 2, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).

NCT ID: NCT02211794 Active, not recruiting - Clinical trials for Degenerative Joint Disease

Journey II BCS EU Observational Trial

Start date: January 2014
Phase:
Study type: Observational

Post-market study to confirm the safety and efficacy of the Journey II BCS knee prosthesis.

NCT ID: NCT02205047 Active, not recruiting - Clinical trials for Malignant Neoplasm of Stomach

Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma

INNOVATION
Start date: July 15, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether either trastuzumab or the combination of trastuzumab and pertuzumab with standard chemotherapy shows more activity against gastro-oesophageal adenocarcinoma than standard chemotherapy given before and after surgery and it can be safely administered.